SGLT2 Inhibitors to Slow Chronic Kidney Disease Progression: A Review
Clin Ther. 2023 Nov 9:S0149-2918(23)00406-X. doi: 10.1016/j.clinthera.2023.10.014. Online ahead of print.ABSTRACTPURPOSE: One in seven Americans is at risk for chronic kidney disease (CKD). For decades, the only treatment proven to slow progression of CKD was the use of renin-angiotensin-aldosterone system inhibitors. Based on promising secondary kidney outcomes in the cardiovascular outcome trials with sodium-glucose co-transporter-2 inhibitors, kidney outcome trials in patients with CKD were published for canagliflozin, dapagliflozin, and empagliflozin.METHODS: A literature search was conducted of PubMed using the MeSH t...
Source: Clinical Therapeutics - November 11, 2023 Category: Drugs & Pharmacology Authors: Rebecca Maxson Jessica Starr Jeanna Sewell Claretha Lyas Source Type: research
Comparative safety of different recommended doses of sodium –glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials
ConclusionCurrent evidence indicated that SGLT-2i did not significantly increase the risk of harm when comparing different doses, except for dapagliflozin 10mg/d, which showed an increased risk of UTI and may be associated with a higher risk of renal impairment and nasopharyngitis. Additionally, compared with placebo and metformin, the risk of GI was notably elevated for empagliflozin 10mg/d, canagliflozin 300mg/d, and dapagliflozin 10mg/d. However, it is important to note that further well-designed RCTs with larger sample sizes are necessary to verify and optimize the current body of evidence.Systematic Review Registratio...
Source: Frontiers in Endocrinology - November 10, 2023 Category: Endocrinology Source Type: research
Sodium-glucose cotransporter –2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
Conclusion SGLT2 inhibitors were associated with a lower reporting probability of fall than DPP4 inhibitors, in accordance with the reassuring evidence about the safety profile of these drugs. Future researches will help to confirm their long-term safety profile. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - November 6, 2023 Category: Drugs & Pharmacology Source Type: research
Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia
This study investigated the effects of canagliflozin therapy on metabolic pathways and inflammation in ischemic myocardial tissue using a swine model of chronic myocardial ischemia. (Source: Surgery)
Source: Surgery - November 6, 2023 Category: Surgery Authors: Dwight D. Harris, Sharif A. Sabe, Cynthia M. Xu, Mohamed Sabra, Mark Broadwin, Akshay Malhotra, Janelle W. Li, M. Ruhul Abid, Frank W. Sellke Source Type: research
Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF- κB and Nrf2/PPAR-γ/SIRT1 signaling pathways
This study aims to provide insights into the potential benefits of canagliflozin as a treatment for UC by addressing possible cellular signals. Acetic acid (AA; 4% v/v) was administered intrarectally to induce colitis. Canagliflozin is given orally at a dose of 10 mg/kg/day. Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-κB-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1β and MPO enzymatic activity. Canagliflozin mitigates colonic oxidative stress by decreasing MDA content and restoring SOD enzymatic ac...
Source: European Journal of Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Hanan S Althagafy Fares E M Ali Emad H M Hassanein Zuhair M Mohammedsaleh Mohamed I Kotb El-Sayed Ahmed M Atwa Ahmed M Sayed Ayman A Soubh Source Type: research
Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF- κB and Nrf2/PPAR-γ/SIRT1 signaling pathways
This study aims to provide insights into the potential benefits of canagliflozin as a treatment for UC by addressing possible cellular signals. Acetic acid (AA; 4% v/v) was administered intrarectally to induce colitis. Canagliflozin is given orally at a dose of 10 mg/kg/day. Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-κB-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1β and MPO enzymatic activity. Canagliflozin mitigates colonic oxidative stress by decreasing MDA content and restoring SOD enzymatic ac...
Source: European Journal of Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Hanan S Althagafy Fares E M Ali Emad H M Hassanein Zuhair M Mohammedsaleh Mohamed I Kotb El-Sayed Ahmed M Atwa Ahmed M Sayed Ayman A Soubh Source Type: research
Canagliflozin ameliorates ulcerative colitis via regulation of TLR4/MAPK/NF- κB and Nrf2/PPAR-γ/SIRT1 signaling pathways
This study aims to provide insights into the potential benefits of canagliflozin as a treatment for UC by addressing possible cellular signals. Acetic acid (AA; 4% v/v) was administered intrarectally to induce colitis. Canagliflozin is given orally at a dose of 10 mg/kg/day. Canagliflozin attenuates inflammation in AA-induced colitis, evidenced by significant and dose-dependently downregulation of p38 MAPK, NF-κB-p65, IKK, IRF3, and NADPH-oxidase as well as colonic levels of IL-6 and IL-1β and MPO enzymatic activity. Canagliflozin mitigates colonic oxidative stress by decreasing MDA content and restoring SOD enzymatic ac...
Source: European Journal of Pharmacology - October 28, 2023 Category: Drugs & Pharmacology Authors: Hanan S Althagafy Fares E M Ali Emad H M Hassanein Zuhair M Mohammedsaleh Mohamed I Kotb El-Sayed Ahmed M Atwa Ahmed M Sayed Ayman A Soubh Source Type: research
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
This article reviews the FDC of canagliflozin with metformin extended release.AREAS COVERED: A literature search was performed to identify publications describing the efficacy and safety of canagliflozin and metformin when used separately and in combinations.EXPERT OPINION: Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which has shown benefits in reducing progression of renal disease and heart failure in patients with T2D. There was an increased incidence of amputation with canagliflozin in one study, but canagliflozin results in weight loss and reduction of blood pressure which contribute to the over...
Source: Expert Opinion on Pharmacotherapy - October 26, 2023 Category: Drugs & Pharmacology Authors: Brian Tomlinson Yan-Hong Li Source Type: research
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
This article reviews the FDC of canagliflozin with metformin extended release.AREAS COVERED: A literature search was performed to identify publications describing the efficacy and safety of canagliflozin and metformin when used separately and in combinations.EXPERT OPINION: Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which has shown benefits in reducing progression of renal disease and heart failure in patients with T2D. There was an increased incidence of amputation with canagliflozin in one study, but canagliflozin results in weight loss and reduction of blood pressure which contribute to the over...
Source: Expert Opinion on Pharmacotherapy - October 26, 2023 Category: Drugs & Pharmacology Authors: Brian Tomlinson Yan-Hong Li Source Type: research
